Surgery Partners, Inc. (NASDAQ: SGRY) is making waves in the healthcare sector, particularly within the medical care facilities industry. With a market capitalization of $1.98 billion, the company stands as a significant player in the U.S. healthcare landscape. Headquartered in Brentwood, Tennessee, Surgery Partners specializes in owning and operating surgical facilities and ancillary services, offering a broad spectrum of non-emergency surgical procedures across various specialties. This includes orthopedics, pain management, ophthalmology, gastroenterology, and general surgery.
As of the latest trading session, Surgery Partners’ stock is priced at $15.17, reflecting a slight decrease of 0.04% from the previous day. The stock’s 52-week range presents a broad spectrum, spanning from $11.49 to $23.84, indicating some volatility but also potential opportunities for investors looking for entry points. Currently, the stock hovers slightly above its 50-day moving average of $14.96 and just below its 200-day moving average of $15.57, suggesting a consolidation phase that could precede a breakout.
Despite not having a trailing P/E ratio or a PEG ratio available, the forward P/E stands at 22.69, offering a glimpse into the valuation based on expected earnings. The company’s revenue growth of 4.50% signals a steady upward trajectory in its financial performance, although the absence of net income and a negative EPS of -0.57 may raise concerns about profitability for some investors. However, a return on equity of 2.75% and a robust free cash flow of approximately $199 million underscore the company’s ability to generate cash and potentially reinvest in growth initiatives.
One of the standout aspects for investors to consider is the analyst sentiment surrounding Surgery Partners. The company boasts nine buy ratings and three hold ratings, with no sell ratings, reflecting strong confidence from the analyst community. The average target price of $18.64 suggests a compelling potential upside of 22.85% from the current price, with target estimates ranging between $14.00 and $24.00. This bullish outlook could be attractive for investors seeking growth opportunities within the healthcare sector.
Surgery Partners does not currently offer a dividend, maintaining a payout ratio of 0.00%, which suggests that the company may be reinvesting earnings back into the business to fuel growth. This approach might appeal to growth-focused investors who prioritize capital appreciation over income generation.
From a technical perspective, the stock’s RSI (14) of 52.64 indicates that it is neither overbought nor oversold, providing a balanced view of current market sentiment. The MACD and Signal Line readings, at 0.10 and 0.32 respectively, imply that the recent momentum is relatively neutral, yet poised for potential positive shifts.
Investors interested in Surgery Partners should consider the company’s strategic position within the healthcare sector, its growth trajectory, and the optimistic analyst ratings. While challenges such as profitability remain, the company’s significant free cash flow and the potential for a 22.85% upside make it a noteworthy candidate for those seeking to capitalize on long-term growth in the healthcare industry. As always, due diligence and a thorough assessment of one’s risk tolerance are advised before making any investment decisions.
